USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PANORAMA RESEARCH
Address:
1230 Bordeaux Dr
Sunnyvale, CA 94089-1202
Phone:
N/A
URL:
N/A
EIN:
943138269
DUNS:
556962439
Number of Employees:
15
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $14,163,583.00 114
SBIR Phase II $12,679,708.00 19

Award List:

PURIFICATION AND CHARACTERIZATION OF A TNF INHIBITOR

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Susan Wright
Abstract:
N/a

PURIFICATION AND CHARACTERIZATION OF A TNF INHIBITOR

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Susan Wright
Abstract:
The overall objective is to purify a novel tumor necrosis factor (tnf)-inhibiting peptide (tnfi) and analyze its potential therapeutic value. the phase i objective is to purify and determine the amino acid sequence of tnfi. culture supernatants harvested from a transformed cell line will be… More

HIV-1 PROTEASE INHIBITORS FROM RANDOM PEPTIDE LIBRARIES

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Robert F Balint
Abstract:
The research is designed to test the feasibility and limits of a novel method developed for theselection of desired biological activities in vivo from random peptide libraries. the method will be adapted for the selection of peptide inhibitors of the hiv-1 protease. the utility of selected… More

CDNA OF JANUSINE, A NOVEL IMMUNOMODULATORY MONOKINE

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
James W Larrick
Abstract:
Hiv infected macrophages release elevated quantities of il1 and a novel 7kd monokine with pleiotropic activities. on the one hand, it inhibits il1 and il6 induced t lymphocyte comitogenesis, but on the other hand, it stimulates b cell mitogenesis. this immunomodulatory monokine is called janusine… More

N/A

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
James W Larrick
Abstract:
N/a

THERAPEUTIC ANTI-METASTATIC ENZYME

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Richard W Hyman
Abstract:
N/a

A RANDOM SINGLE CHAIN ANTIBODY LIBRARY

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
James W Larrick
Abstract:
N/a

Novel Immunosuppressive Antibody

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
K31 is a promising murine anti-CD48 monoclonal antibody (MAB) which can deplete tissue grafts of antigen presenting accessory cells to reduce their immunogenicity. Because any in vivo use of this MAB will be limited by the human anti-mouse antibody (HAMA) response, the overall goal is to use PCR… More

Gene Therapy for Hepatocellular Carcinoma

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
Therapeutic options for hepatocellular carcinoma (HCC) are limited and the results of therapy are dismal. Previous work from this laboratory demonstrated that cationic liposomes can deliver indicator transgenes to liver and lymphoid cells in vivo. We will apply these techniques to HGG by delivering… More

Mabzymes to Activate Anticancer Glucuronide Prodrugs

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
Cancer chemotherapy is limited by toxicity sustained by normal tissues. To increase specificity of drug delivery, antineoplastic agents have been linked to monoclonal antibodies (MABs) that bind to antigens selectively expressed on tumor cells. However, this strategy suffers from several drawbacks.… More

Humanized Anti-B7 Mab for Transplant Rejection

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
Optimal therapy to prevent graft rejection should be based on the induction of specific tolerance to the donor tissue. Current concepts on immunological tolerance hold that anergy is the result of intercellular signalling after TCR/MHC-peptide interaction in the absence of a so- called Costimulatory… More

Novel Gene Delivery Technique for Organ Transplantation

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$49,950.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
Therapeutic options for hepatocellular carcinoma (HCC) are limited, and the results of therapy are dismal. Previous work from this laboratory demonstrated that cationic liposomes can deliver indicator transgenes to liver and lymphoid cells in vivo. We will apply these techniques to HCC by delivering… More

Cloning of a Novel Therapeutic Hepatokine

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
Hepatokines are autocrine or paracrine growth factors for liver tissue. The hepatopoietin described is a novel hepatocyte-specific growth factor. In preliminary work, hepatopoietin was purified to homogeneity (based on SDS-PAGE, reverse phase HPLC and capillary electrophoresis) and found to have a… More

Novel Sensitive Test for Gram-Negative Sepsis

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
N/a

A RANDOM SINGLE CHAIN ANTIBODY LIBRARY

Award Year / Program / Phase:
1994 / SBIR / Phase II
Award Amount:
$470,811.00
Agency:
HHS
Principal Investigator:
James W Larrick
Abstract:
The overall goal of this project is to construct a single chain antibody (sc-ab) expression library. degenerate pcr primers will be used to amplify antibody heavy and light chain variable regions. heavy and light chains will be recombined in vitro using pcr and linked witha 42 bp spacer arm to make… More

Antigen Dependent Amplification of Phage Antibodies

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
James Larrick
Abstract:
Antigen specific selection of antibodies (or other proteins) expressed on the surface offilamentous phage has previously been performed by affinity enrichment on columns or by panning. Avaluable addition to this methodology would be to link receptor-ligand binding in a manner similar toclonal… More

Preclinical Study of a Novel LPS Inhibitor

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$78,537.00
Agency:
HHS
Principal Investigator:
James Larrick
Abstract:
Gram negative bacterial infections continue to account for significant mortality and morbiditydue the inability of new antibiotics to neutralize the deleterious effects of lipopolysaccharide (LPS)released from the bacterial cell surface. LPS initiates an immunoinflammatory cascade characterized… More

Aposcreen--A Novel Test for Tumor Promoters

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$71,730.00
Agency:
HHS
Principal Investigator:
Susan Wright
Abstract:
Currently there are a variety of in vitro screening assays used to test environmental compoundsand potential drugs for mutagenic and carcinogenic activity. However, these assays generally do notdetect tumor promoters, thus economical screens for these agents are urgently needed. This applicationwill… More

Novel Transcription Factor Selection System

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Robert Balint
Abstract:
The expression of many inducible genes is regulated at the level of mRNA transcription. Thepromoter regions of these genes are comprised of regulatory sequences that bind a specific combinationof transcription factors. Our aim is to identify and clone novel transcription factors specific… More

Engineered Human Antibodies for Breast Cancer

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Robert Balint
Abstract:
The HER2 (c-erbB-2) proto-oncogene is over-expressed in approximately 30% of the>160,000/yr new cases of breast and ovarian cancer, and correlates inversely with prognosis. Whileanti-erbB-2 antibodies and immunoconjugates show much promise for breast cancer therapy, a fullyhuman high-affinity… More

Novel Sensitive Test for Gram-Negative Sepsis

Award Year / Program / Phase:
1994 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
Approximately 40% of patients suffering from the sepsis syndrome are infected with Gram negative bacteria. It is this subset of patients that stand to benefit from new therapies designed to neutralize endotoxin such as anti-lipid A monoclonal antibodies (e. g. E5 or HA-1A) and bacterial permeability… More

THERAPEUTIC ANTI-METASTATIC ENZYME

Award Year / Program / Phase:
1995 / SBIR / Phase II
Award Amount:
$467,656.00
Agency:
HHS
Principal Investigator:
Richard W Hyman
Abstract:
Published data suggests that reduced serum tyrosine and phenylalanine concentrations reduce the number of metastasis in various animal cancer models as well as human patients. the longterm goal of this work is to clone, express and evaluate therapeutic enzymes that catabolize one or both of these… More

Protease Resistant C1 Inhibitor for Sepsis

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
James Larrick
Abstract:
Activation of both the complement and the contact systems of intrinsic coagulation are implicated ipathophysiology of sepsis. C1-inhibitor (C1-INH) is a member of the superfamily of serine protease ithe major inhibitor of both factor XIIa and kallikrein of the contact system and also the only… More

High Throughput Screen for Inhibitors of Bcl 2

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$99,640.00
Agency:
HHS
Principal Investigator:
Anthony Davies
Abstract:
Deregulation of the bcl-2 oncogene underpins both the etiology and the chemoresistance of many signtumors. The Bcl-2 protein mediates these effects by blocking physiological (programmed) cell death (malignant cells. In vitro models indicate that inhibitors of bcl-2 gene expression block this… More

Ligand Selection by Rescue of Phage Infectivity

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$85,559.00
Agency:
HHS
Principal Investigator:
Robert Balint
Abstract:
N/a

Novel Therapy for Dental Caries

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
James Larrick
Abstract:
N/a

Novel Therapy for Cryptosporidium Parvum Diarrhea

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
James Larrick
Abstract:
N/a

N/A

Award Year / Program / Phase:
1996 / SBIR / Phase II
Award Amount:
$476,004.00
Agency:
HHS
Principal Investigator:
James W Larrick
Abstract:
N/a

NOVEL VISUAL IMMUNOASSAY (VIA) FOR STDS

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

NOVEL VACCINE FOR HELICOBACTER PYLORI

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

NOVEL ANTIGEN ANALOG LIBRARIES FOR AUTOIMMUNE THERAPY

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$96,467.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

EXPRESSION LIBRARIES IN RECOMBINANT BACULOVIRUSES

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$93,943.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

B7 IMMUNOTOXINS FOR IMMUOTHERAPY

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

ULTRASOUND-MEDIATED GENE TRANSFER

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

SBIR PHASE I: Novel Pest Control Using Contraceptive Vaccines Produced in Plants

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
NSF
Principal Investigator:
Andrew Hiatt
Abstract:
N/a

Novel Therapy for Dental Caries

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
James Larrick
Abstract:
Our research is based on the report that certain monoclonal antibodies that recognize a 185kDa surfantigen present on the cariogenic bacterium, Streptococcus mutants, when applied to human teeth, aftprofessional cleaning and chlorhexidine treatment, prevent recolonization of the mouth by S.… More

Novel Therapy for Cryptosporidium Parvum Diarrhea

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
James Larrick
Abstract:
Cryptosporidium parvum is a major cause of diarrhea disease among immunocompromised AIDS patients wlimited treatment options. The overall goal of the present proposal is to develop therapeutic plantiassociated diarrhea diseases. This approach will provide a novel and inexpensive means to prevent… More

Ligand Selection by Rescue of Phage Infectivity

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Robert Balint
Abstract:
Improved methods for the identification of physiologically important protein-protein interactions ademand. We Have devised a novel system which allows the selection of protein or peptide ligands of afrom complex mixtures by virtue of their ability to facilitate the replication of their own genes.… More

CTLA4-IG-ANTICD40 FUSION PROTEIN FOR IMMUNOTHERAPY

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Larrick, james w
Abstract:
N/a

NOVEL THERAPY FOR CHEMOTHERAPY ALOPECIA

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Larrick, james w
Abstract:
N/a

NOVEL HEPATOPOIETIN FOR HEPATOCELLULAR INJURY

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Larrick, james w
Abstract:
N/a

ENGINEERING CATALYTIC ANTIBODIES FOR CANCER THERAPY

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Balint, robert f
Abstract:
N/a

NOVEL NMDA RECEPTOR ANTAGONISTS FOR HIV NEUROINJURY

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Wang, yuqiang
Abstract:
N/a

NOVEL THERAPY FOR STAPHYLOCOCCUS AUREUS

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Larrick, james w
Abstract:
N/a

NOVEL VISUAL IMMUNOASSAY (VIA) FOR STDS

Award Year / Program / Phase:
1998 / SBIR / Phase II
Award Amount:
$677,466.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

HOMOGENEOUS HEMAGGLUTINATION ASSAY FOR HIV

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Larrick, James W
Abstract:
N/a

NOVEL IMMUNOTHERAPY FOR HELICOBACTER PYLORI

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Larrick, James W
Abstract:
N/a

NOVEL PROTEASE INHIBITOR TO PREVENT PATHO-APOPTOSIS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Wright, Susan C
Abstract:
N/a

NOVEL ASSAY FOR VASCULAR DISEASE RISK ASSESSMENT

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Balint, Robert F
Abstract:
N/a

NOVEL THERAPY FOR THE COMMON COLD

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Larrick, James W
Abstract:
N/a

SYNTHESIS AND ANTITUMOR EVALUATION OF CC1065 ANALOGS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Wang, Yuqiang
Abstract:
N/a

NOVEL STAPHYLOCOCCUS AUREUS VACCINE STRATEGY

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Larrick, James W
Abstract:
N/a

STABLE FOLD SELECTION FOR HETEROLOGOUS PROTEINS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Balint, Robert F
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase II
Award Amount:
$709,817.00
Agency:
HHS
Principal Investigator:
Larrick James W
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase II
Award Amount:
$750,011.00
Agency:
HHS
Principal Investigator:
Wang yuqiang
Abstract:
N/a

HIGH THROUGHPUT INTERACTION MAPPING OF HUMAN PROTEOMES

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Robert F. Balint
Abstract:
Not Available SY Technology, Inc. proposes to develop a smart camera to automatically identify regions of interest (ROI) in imagery. The camera has two target recognition applications. First, to process a correlation surface (obtained by correlating an image with a filter) to identify, enhance and… More

APOPTOSIS INHIBITOR FOR ALOPECIA DUE TO CANCER THERAPY

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Susan C. Wright
Abstract:
Not Available ISC will develop a miniaturized uncooled thermal imaging sighting system for handheld weapons, including the MP5, M-4, Sig-Sauer P226, and the Beretta 9mm semi-automatic pistol, that not affect the accuracy or the operation of the weapon. This system will include a totally passive… More

NATURAL INHIBITOR OF INFLAMMATORY CASCADE

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Susan C. Wright
Abstract:
Not Available Polarization imaging holds promise for providing significant improvements in contrast in a number of target detection and discrimination applications. It has been demonstrated that manmade objects have a significantly stronger polarization signal than natural backgrounds. There is… More

HIGH THROUGHPUT SELECTION OF FABS TO THE HUMAN PROTEOME

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Robert F. Balint
Abstract:
Not Available There is an increasing desire in many organizations, including the Department of Defense, NASA, and commercial satellite operators, to use constellations or fleets of autonomous spacecraft working together to accomplish complex mission objectives. Multiple satellite systems are… More

NOVEL THERAPY FOR CANDIDA ALBICANS INFECTION

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$93,216.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
Not Available The Kinetic Kill Vehicle Hardware In the Loop Simulation (KHILS) facility requires a Visible Wavelength Scene Projection system for HIL testing of visible sensors. The Visible Projector must meet stressing performance requirements in order to provide valid and credible test results on… More

NOVEL THERAPY FOR CLOSTRIDIUM DIFFICILE DIARRHEA

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,827.00
Agency:
HHS
Principal Investigator:
Keith L. Wycoff
Abstract:
Not Available This research will develop principles and plans for a user-focused architecture for embedded applications for war fighters. The concept of a user-focused architecture is based on new, sophisticated system services centered in the user interface. These services will allow the user to… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$105,632.00
Agency:
HHS
Principal Investigator:
Susan C. Wright
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$120,183.00
Agency:
HHS
Principal Investigator:
Susan C. Wright
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$114,480.00
Agency:
HHS
Principal Investigator:
Robert F. Balint
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$102,841.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$375,000.00
Agency:
HHS
Principal Investigator:
Robert F. Balint
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Robert F. Balint
Abstract:
N/a

SIGNAL TRANSDUCTION BIOSENSORS FOR ANTI-CANCER HTS

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Robert F. Balint
Abstract:
DESCRIPTION (applicant's abstract): The Achilles heel of most current high-throughput screening (HTS) strategies is the inherent inefficiencies of the available screening assay platforms, leading to excessive rates of false positive and false negative selection. To… More

Novel Therapy for Staphylococcal Infection

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$387,424.00
Agency:
HHS
Principal Investigator:
Susan C. Wright
Abstract:
The emergence of antibiotic-resistant Staphylococcus aureus has created an urgent need for new therapeutic approaches to treat the variety of diseases caused by this common pathogen. S. aureus damages host tissues by the secretion of a variety of toxic exomolecules known as virulence factors. The… More

Novel Therapy for the Common Cold

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
The common cold is generally not life threatening to most people, but does cause significant morbidity and loss of productivity. For some, particularly those with asthma or who are immunocompromised, it can be quite serious. Prospects are in hand for development of a new therapeutic that could have… More

Novel Therapy for the Common Cold

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$455,650.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
The common cold is generally not life threatening to most people, but does cause significant morbidity and loss of productivity. For some, particularly those with asthma or who are immunocompromised, it can be quite serious. Prospects are in hand for development of a new therapeutic that could have… More

Novel Therapy for Staphylococcal Infection

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Susan C. Wright
Abstract:
The emergence of antibiotic-resistant Staphylococcus aureus has created an urgent need for new therapeutic approaches to treat the variety of diseases caused by this common pathogen. S. aureus damages host tissues by the secretion of a variety of toxic exomolecules known as virulence factors. The… More

Non-toxic Cancer Therapy

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Susan C. Wright
Abstract:
DESCRIPTION (provided by applicant): The present application is based on the remarkable finding that non-calorigenic thyroid hormones mediate tumor cell apoptosis. A selected lead compound has been identified and shown to interact with microtubules. This compound, DIME, is… More

SYNTHESIS AND EVALUTATION OF CATIONIC ANTITUMOR AGENTS

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$244,392.00
Agency:
HHS
Principal Investigator:
Yuqiang Wang
Abstract:
N/a

NOVEL THERAPY FOR ALLERGIC DISEASE

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
James W. Larrick
Abstract:
DESCRIPTION: Eosinophils play a central role in the pathogenesis of allergic diseases. The present application is based on the remarkable finding that sulochrin, a metabolite of Aspergillus, can specifically inhibit eosinophil effector function. The overall goal of this… More

HUMAN ANTIBODY IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$131,241.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by the applicant): The plaques characteristic of Alzheimer?s disease result in part from the abnormal deposition of the peptide beta-amyloid (Abeta). Recent work of Schenk et al. (1999) using a transgenic mouse model of Abeta deposition demonstrated the remarkable capacity… More

NOVEL ANTI-QUORUM SENSING AGENT

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (Provided by applicant): The opportunistic human pathogen P. aeruginosa utilizes N-acylhomoserine lactones as quorum sensing "autoinducers" to specifically induce numerous virulence genes. AiiA is the first enzyme known to inactivate N-acylhomoserine lactones. Expression of AiiA in… More

NOVEL NMDA RECEPTOR-BINDING DRUGS FOR ISCHEMIA/STROKE

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to develop a novel therapy for neurological injury. The concept is to combine two mechanisms known to provide neuroprotection from ischemic damage. Thus, we will combine a nitrone, known to have potent free radical scavenging… More

Novel Antimicrobial Therapy

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The 18-kD cationic protein CAP18 is an antimicrobial protein first isolated from rabbit granulocytes that binds lipopolysaccharide and inhibits many of its biological activities (Larrick et al., 1995). The most active approximately 30 amino acid fragment of… More

Synthesis and Evaluation of Novel Antitumor Agents

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Recently, tumor cells have been found to selectively accumulate certain n-3 fatty acids such as cis-4,7,10,13,16,19-docosahexenoic acid (DHA). DHA-paclitaxel, a conjugate of DHA and paclitaxel, has greatly increased therapeutic efficacy and reduced side effects… More

An Endogenous Cardioprotectant

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$98,007.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Des-asp angiotensin 1 (DAA-1) is a potent endogenous cardiovasculo-protective peptide generated from angiotensin 1 by a novel aminopeptidase. DAA-1 given both iv and po has sub-micromolar protective activity in a number of cardiac and renal pathophysiology. These… More

Novel Immunoadhesin Molecule for Cancer Therapy

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$106,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Hepatocyte growth factor (HGF) and its receptor, c-Met, are known to play an important role in tumor growth, metastasis and angiogenesis. Met is widely expressed on various types of tumor cells. Thus, an antagonist molecule that blocks the HGF-Met interaction is… More

A Novel Technology for Molecular Evolution

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$107,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The post-genomics era will demand high throughput technologies to generate and evolve proteins and protein-binding molecules. The overall goal of this work is to develop a novel ribo-display technology for in vitro molecular evolution. Preliminary work provides… More

Novel Antibody-Based Therapy for Autoimmune Disease

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$140,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by the applicant): Intravenous gamma globulin (IVIG) is a remarkably safe and effective therapy for a number of autoimmune diseases. Recent studies indicate that the binding of Ig Fc to the neonatal Fc receptor determines the half-life of antibodies in vivo. In addition, the… More

A Novel Hepatokine

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Hepatokines are hepatocyte-derived autocrine or paracrine growth and survival factors. Preliminary data described below demonstrates the identification of a novel hepatokine (HK-1) originally isolated from fetal hepatocytes and patented by this laboratory. The… More

Antagonism of PAMP, a potent angiogenic factor

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$129,608.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Recent clinical results with angiogenesis-inhibiting biopharmaceuticals have validated this class of therapeutics as important anti-cancer agents. The most promising therapeutic candidates to date interfere with proangiogenic stimulation by VEGF. Our… More

Small Molecule Inhibitor of Quorum Sensing

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$112,350.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The opportunistic human pathogen, Pseudomonas aeruginosa, utilizes acyl-homoserine lactones (acyI-HSL) as quorum sensing autoinducers to activate the expression of numerous virulence genes. Some virulence factors are directly toxic to host tissues while others… More

Novel Immunotherapy for Hepatocellular Carcinoma

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$100,005.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is one the most common forms of cancer worldwide, with approximately 1,000,000 new cases and 1,300,000 deaths reported annually. It is one of the most lethal forms of cancer, in part due to the fact that HCC cells are highly… More

Novel Monoclonal Antibody Therapy for Cancer

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this work is to develop a novel monoclonal antibody for cancer therapy. HGF is a paracrine angiogenic factor and an autocrine growth factor for many different types of cancer cells. Thus antagonistic monoclonal antibodies to HGF are expected… More

Novel Tumor-selective Anticancer Agents

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$146,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Recently, tumor cells have been found to selectively accumulate certain n-3 fatty acids such as cis-4,7,10,13,16,19-docosahexenoic acid (DHA). DHA-paclitaxel, a conjugate of DHA and paclitaxel, has a greatly increased therapeutic efficacy and reduced side… More

Pathogen Detection with Immunological Capture and BRC

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this technology development program is improve the detection and quantitation of specific microbes in biological fluids such as blood, cerebrospinal fluid and urine. This technology is based upon a novel enzymatic amplification system called… More

Myocardial repair by targeted stem cells

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$105,735.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Published data indicates that bone marrow-derived stem cells injected directly into injured myocardium provides improvement in left ventricular function post-myocardial infarction. Our collaborator, Dr. Randy Lee at UCSF, has developed an alternative proprietary… More

Anti-Pseudomonas Biofilm Therapy for Cystic Fibrosis

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): CF is an autosomal recessive genetic disorder affecting approximately 30,000 patients in the United States and 60,000 patients worldwide, with an average life expectancy of about 30 years. Lung infection with Pseudomonas aeruginosa is a leading cause of… More

Novel Therapy for Hepatocellular Carcinoma

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$133,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is among the world's most common and lethal malignancies with no effective therapy. Because of the normal function of the liver to detoxify xenobiotics, cancers of this tissue are notoriously resistant to chemotherapy. Furthermore,… More

Antibody Therapy Targeting a Novel Neuroblastoma Antigen

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$130,270.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Neuroblastoma is the most common extracranial solid tumor of childhood. Aggressive chemotherapy and surgery have improved remission rates for young patients, but not for adolescents or adults, in whom neuroblastoma is especially resistant to chemotherapy. Thus,… More

Novel Lipid Mobilizing Factor for Obesity

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$140,468.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Obesity is a growing major medical problem worldwide. It is the second most important cause of preventable death in the US, exceeded only by cigarette smoking. Current treatments consist of diet, exercise, behavior modification, surgical intervention, and… More

Novel display system for antibody affinity maturation

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$99,998.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The use of antibodies as therapeutic agents has gained increasing acceptance over the last several years, and there are currently 18 FDA-approved monoclonal antibody therapies. The main advantages of antibody-based therapy over traditional, small molecule… More

Novel Immunoadhesin Molecule for Cancer Therapy

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$788,835.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall objective of this application is to perform necessary studies in preparation for conducting clinical trials in cancer of an immunoadhesin that neutralizes hepatocyte growth factor (HGF). Previously, a Met-Fc immunoadhesion was developed that inhibits… More

Targeted Enzyme for HCC

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$158,841.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Primary liver cancer, hepatocellular carcinoma (HCC) is one of the most common forms of cancer worldwide, causing an estimated 1.3M deaths annually (Venook, 1994). Because HCC is often detected only in late stages, it is one of the most lethal forms of cancer,… More

Novel Therapy for Diabetic Complications Using RAGE-Fc

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$148,400.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Recent investigations demonstrate the importance of receptor for advanced glycation end products (RAGE) mediated signal transduction in promoting pathogenic inflammation, renal failure and diabetic complications. Animal studies indicate that the extracellular… More

Novel Multiplex Assay for Biomarkers of Obstructive Nephropathy

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$106,050.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Congenital obstructive nephropathy is the most frequent cause of renal failure in infants and children, and if left untreated can cause severe renal failure and death. Challenges in the evaluation and management include the lack of clear indications if and when… More

Novel Multiplex Assay for Sepsis Biomarkers

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$542,920.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Severe sepsis is the leading cause of death in intensive care units and accounts for 9.3% of overall deaths in the United States annually (Angus, 2001). This complex disorder is difficult to diagnose and treat, and ther e is a great need for a test that can… More

Enhanced Engraftment of Stem Cells

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$201,650.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Enhanced engraftment of stem cells. There is an urgent need for methods to improve the engraftment efficiency of autologous and allogeneic hematopoietic stem cells (HSC) after myeloablative therapy. Although mobilized p eripheral blood and umbilical cord blood… More

Novel BiSpecific Antibodies

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$190,350.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Novel Bispecific Antibodies Bispecific antibodies (BiAb) are a promising class of protein pharmaceuticals utilized to target and/or redirect therapeutic cells. Numerous BiAbs are under development to direct activated T cells to tumors. Our laboratory (Lee, 2006)… More

Rational Psoriasis Therapy

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$189,720.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Proteolytic antibodies ( Proteo-abzymes ) are a novel therapeutic modality that has the potential to revolutionize antibody-based therapeutics. The overall goal of this project is to develop potent proteolytic anti-amph iregulin (AR) human monoclonal antibodies… More

Anti-inflammatory Nicotinic Agonists for Therapy of Ulcerative Colitis

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$103,300.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Ulcerative colitis (UC) is a chronic tissue-destructive disease in which cellular inflammation and inflammatory cytokines ultimately lead to damage of the colonic mucosa. There is no effective cure, and while standard t herapies can ameliorate symptoms in some… More

Myocardial Repair by Targeted Stem Cells

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$1,735,802.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There is an urgent need for improved therapies for acute and chronic myocardial ischemia. Bone marrow-derived stem cells (SC) injected into acutely injured as well as chronically ischemic myocardium improve left ventric ular function. However, a major limitation… More

Kinetic Assembly of Bispecific Antibodies

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$170,289.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Kinetic Assembly of Bispecific Antibodies Bispecific antibodies (BiAb) are a promising class of protein pharmaceuticals utilized to target and/or redirect therapeutic cells as well as overcome regulatory hurdles for th erapies affecting two targets. Numerous… More

Novel Therapy for Diabetic Complications Using RAGE-Fc

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$613,273.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Recent investigations demonstrate the importance of receptor for advanced glycation end products (RAGE) mediated signal transduction in promoting pathogenic inflammation, renal failure and diabetic complications. Anima l studies indicate that the extracellular… More

Novel Therapy for Chronic Non-healing Wounds

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$143,100.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): ABSTRACT: A significant need exists to address complications associated with the growing pandemic of diabetes mellitus and metabolic syndrome now estimated to affect gt20 million people in the United States (~7% of the population ). Impaired wound repair, a… More

Novel TACE Inhibitors for Breast Cancer Therapy

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$192,060.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Breast cancer is the most frequently diagnosed cancer in the US with an estimated 211,240 new cases of invasive breast cancer and 58,490 new cases of in situ breast cancer in 2005. The mortality rate of 2.3% per year tr anslates into more than 40,000 deaths of… More

Multiplex Biomarkers for Prostate Cancer

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$198,821.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Prostate cancer is the most common malignancy and second-leading cause of cancer deaths among males in the United States, accounting for 1/3 of all new cancers in males with an estimated 232,090 new cases yearly (Jemal, 2005). The mainstay of prostate cancer… More

Novel Therapy for Pemphigus Vulgaris by Treatment with a Cholinergic Agonist

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$175,408.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Pemphigus vulgaris (PV) is a chronic autoimmune disease targeting skin and mucous membranes, characterized by intraepithelial aphlegmasic flaccid blisters and erosions. It is caused by pathogenic autoantibodies that in duce the separation of keratinocytes (KC)… More

Novel Multiplex Assay for Biomarkers of Alzheimer's Disease

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$161,700.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's disease (AD), the most common form of dementia, is a complex disorder that is difficult to diagnose and treat. Currently, there is no readily available biomarker test panel to aid diagnosis or monitor disea se progression. Although analysis of… More

Inotropic Antibodies

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$198,909.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): An urgent need exists to develop novel therapies for cardiac failure. The Na+/K+ ATPase (NKA) catalyzes active transport of Na+ and K+ ions across the cardiomyocyte plasma membrane. Cardiac glycosides are thought to ha ve a positive inotropic effect by… More

Tissue Repair During Acute Phase of Myocardial Infarction

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$230,586.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Tissue Repair During Acute Phase of Myocardial Infarction Cardiovascular disease is the leading cause of mortality and morbidity in developed countries. Each year, over 19 million incidents of sudden cardiac events occu r worldwide, with approximately 1 million… More

Trophokine for regenerative medicine

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$199,800.00
Agency:
HHS
Principal Investigator:
Jianmin Fang
Abstract:
DESCRIPTION (provided by applicant): Hepatocyte growth factor (HGF) is a pleiotropic cytokine that promotes cell proliferation, motility, survival, and morphogenesis. HGF binds to its receptor c-Met tyrosine kinase and triggers signal transduction that pro tects cells against apoptosis and enhances… More

Anti-inflammatory Nicotinic Agonists for Therapy of Ulcerative Colitis

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$1,072,338.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Ulcerative colitis (UC) is a chronic tissue-destructive disease in which cellular inflammation and inflammatory cytokines ultimately lead to damage of the colonic mucosa. There is no effective cure, and while standard therapies can ameliorate symptoms in some… More

Improved Therapy for AMD

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$200,786.00
Agency:
HHS
Principal Investigator:
Jianmin Fang
Abstract:
DESCRIPTION (provided by applicant): Improved therapy for AMD Age-related macular degeneration (AMD) is a leading cause of visual loss (http://www.nei.nih.gov/eyedata/pbd4.asp) affecting more than 1.75 million people in the USA. Vascular endothelial growt h factor (VEGF) is a major driver of… More

Novel Regenerative Therapy for Myocardial Infarction

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$289,018.00
Agency:
HHS
Principal Investigator:
Andrew R. Mendelsohn – 650-694-4996
Abstract:
DESCRIPTION (provided by applicant): A Novel Regenerative Therapy for Myocardial Infarction Myocardial infarction (MI) is an acute public health problem killing one third of the 1.5 million Americans afflicted annually. Almost all MIs are caused by ruptureof coronary atherosclerotic plaques with… More

Monobody for Renal Inflammaton

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$241,123.00
Agency:
HHS
Principal Investigator:
James W. Larrick – 415-264-6311
Abstract:
DESCRIPTION (provided by applicant): Monobody for Renal Inflammation End stage renal disease (ESRD) affects gt485,000 Americans, including over 341,000 hemodialysis patients with an estimated 90,000 new cases per year. The annual cost of treating Americanssuffering from some form of kidney failure… More

Gratuitous Inducer for Industrial Enzyme Production

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$98,739.00
Agency:
USDA
Principal Investigator:
Tom T. Huang, Senior Research Scientist – 650-391-7805
Abstract:
Cellulose is the most abundant biopolymer on earth. Photosynthesis produces biomass containing over a trillion tons of cellulose annually. This almost inexhaustible source of building blocks for biofuels, bioplastics, and other biochemicals, is key to a renewable, non-petroleum-based chemicals… More

A Novel Hybrid Multifunctional Cytokine for Immune Reconstitution

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$227,861.00
Agency:
HHS
Principal Investigator:
Susan C. Wright – 650-694-4996
Abstract:
DESCRIPTION (provided by applicant): The goal of this proposal is to develop a novel hybrid bifunctional cytokine ( fusokine ) to promote immune reconstitution and inhibit graft-versus-host disease (GVHD) in cancer patients undergoing hematopoietic stemcell transplantation. The fusokine, termed… More

Hetero-dimerization-activated Antibodies

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$295,502.00
Agency:
HHS
Principal Investigator:
James W. Larrick – 415-264-6311
Abstract:
DESCRIPTION (provided by applicant): The targets of most therapeutic antibodies are found on healthy cells which limits the development of truly tumor-specific therapies and results in a narrow therapeutic index. Using state-of-the-art proteomic and geneprofiling methods, our collaborators have… More

Novel anti-ganglioside therapy

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$294,070.00
Agency:
HHS
Principal Investigator:
James W. Larrick – 415-264-6311
Abstract:
DESCRIPTION (provided by applicant): Disialoganglioside GD2+ tumors account for ~10% of cancer deaths. Anti-GD2 antibody therapies have shown promise in advanced clinical trials in melanoma, neuroblastoma, and other tumors. However, current antibody approaches suffer from significant neurotoxicity… More

Novel Therapy for Preeclampsia

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$226,814.00
Agency:
HHS
Principal Investigator:
James W. Larrick – 415-264-6311
Abstract:
DESCRIPTION (provided by applicant): Preeclampsia (PE) is a serious complication of pregnancy manifested by high blood pressure, proteinuria, and edema, sometimes with encephalopathy, seizures, and hepatic failure. PE complicates from 5 to 10% of pregnancies, and is a major cause of maternal and… More

Using Aldehyde Tags to Generate Site-Specifically Modified Antibody Drug Conjugat

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$293,355.00
Agency:
HHS
Principal Investigator:
James W. Larrick – 415-264-6311
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a therapy for neurodegenerative tauopathies that uses a recombinant adeno- associated viral (AAV) vector to achieve long-term, stable central nervous system (CNS) delivery of a therapeutic tau N-terminal antibody (TNT-Ab). To this end, we… More

Adipokine Secretion Enhancer Synthetic Organic Drug Discovery in Human Adipocytes

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$315,527.00
Agency:
HHS
Principal Investigator:
Susan C. Wright – 650-694-4996
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is the preclinical development of a novel Rho kinase inhibitor (TRX-101) as a new therapy for scleroderma/systemic sclerosis (SSc). SSc is a chronic disease of unknown etiology characterized by severe and often progressive… More

Primary Screener for Mathematics (PSM) and Diagnostic Assessment of Math Skills

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$267,743.00
Agency:
HHS
Principal Investigator:
Susan C. Wright – 650-694-4996
Abstract:
DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) is the most common cause of end-stage renal disease (ESRD) in the world and affects about 15-25% of type I diabetes patients and 30-40% of patients with type II diabetes. The development of DNis thought to result from the cumulative… More

Hepcidin Replacement Therapy for Iron Overload Disorders

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$289,062.00
Agency:
HHS
Principal Investigator:
James W. Larrick – 415-264-6311
Abstract:
DESCRIPTION (provided by applicant): Iron-overload disorders, including hereditary hemochromatosis, are typically insidious, causing progressive and sometimes irreversible end-organ injury before clinical symptoms develop. Iron overload in vital organs increases the risk for liver disease… More

Scale-up of Gratuitous Inducer for Industrial Enzyme Production

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$449,621.00
Agency:
USDA
Principal Investigator:
Tom T. Huang, President&Chief Scientific Officer – 650-391-7305
Abstract:
We have identified methods to produce inducers of cellulase production that will streamline the production of these enzymes for cellulosic ethanol and other applications. During Phase II of this project, we will scale up the methods, determine their applicability to commercially relevant hosts, and… More